Patents Assigned to MAMMOTH BIOSCIENCES, INC.
  • Patent number: 11814620
    Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins are shown to be active with guide RNAs and may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.
    Type: Grant
    Filed: May 17, 2022
    Date of Patent: November 14, 2023
    Assignee: Mammoth Biosciences, Inc.
    Inventors: Benjamin Julius Rauch, Aaron DeLoughery, William Douglass Wright, David Paez-Espino, Clarissa Oriel Rhines, Lucas Benjamin Harrington, Wiputra Jaya Hartono
  • Patent number: 11761029
    Abstract: Described herein are devices, systems, fluidic devices, kits, and methods for detection of target nucleic acids associated with diseases, cancers, genetic disorders, a genotype, a phenotype, or ancestral origin. The devices, systems, fluidic devices, kits, and methods may comprise reagents of a guide nucleic acid targeting a target nucleic acid, a programmable nuclease, and a single stranded detector nucleic acid with a detection moiety. The target nucleic acid of interest may be indicative of a disease, and the disease may be communicable diseases, or of a cancer or genetic disorder. The target nucleic acid of interest may be indicative of a genotype, a phenotype, or ancestral origin.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: September 19, 2023
    Assignee: MAMMOTH BIOSCIENCES, INC.
    Inventors: Janice Sha Chen, Ashley Tehranchi, Andrew Besancon Lane, James Paul Broughton, Lucas Benjamin Harrington, Maria-Nefeli Tsaloglou, Xin Miao, Clare Louise Fasching, Jasmeet Singh, Pedro Patrick Draper Galarza
  • Patent number: 11273442
    Abstract: Described herein are devices, systems, fluidic devices, kits, and methods for detection of target nucleic acids associated with diseases, cancers, genetic disorders, a genotype, a phenotype, or ancestral origin. The devices, systems, fluidic devices, kits, and methods may comprise reagents of a guide nucleic acid targeting a target nucleic acid, a programmable nuclease, and a single stranded detector nucleic acid with a detection moiety. The target nucleic acid of interest may be indicative of a disease, and the disease may be communicable diseases, or of a cancer or genetic disorder. The target nucleic acid of interest may be indicative of a genotype, a phenotype, or ancestral origin.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: March 15, 2022
    Assignee: MAMMOTH BIOSCIENCES, INC.
    Inventors: Janice Sha Chen, Ashley Tehranchi, Andrew Besancon Lane, James Paul Broughton, Lucas Benjamin Harrington, Maria-Nefeli Tsaloglou, Xin Miao, Clare Louise Fasching, Jasmeet Singh, Pedro Patrick Draper Galarza
  • Patent number: 11174470
    Abstract: Disclosed herein are compositions, kits, and methods related to improved Cas activity. Through compositions and kits disclosed herein and practice of methods disclosed herein, one attains improved Cas activity such as Cas12 activity relative to Cas proteins in the art such as LbCas12. Further described herein are methods to detect target nucleic acid using a programmable nuclease system. Often, the target nucleic acids are present in at low frequency in the sample. Provided herein are methods for enriching these target nucleic acids for detection. Also described herein are methods to insert a PAM sequence into a target sequence of interest for use in a detection comprising a programmable nuclease.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: November 16, 2021
    Assignee: MAMMOTH BIOSCIENCES, INC.
    Inventors: Lucas Benjamin Harrington, Janice Sha Chen, James Paul Broughton, Pedro Patrick Draper Galarza, Wiputra J. Hartono, Isaac Paterson Witte, Jasmeet Singh